|
|
|
Pharmaceutical Manufacturing and Packing Sourcer
|
The inhalation of liquid droplets has been studied and developed since the mid 1840s when Charriere in France constructed the first liquid pulverisation device (nebuliser) for Sales-Girons. This triggered the development of smaller and more convenient table top jet nebuliser devices. In the early 20th Century these were adapted into hand-held, glass blown devices powered by a rubber 'herons' ball operated by the user. In the mid 1940s small electrical compressors were becoming more available and in the early 1960s the plastic jet nebuliser was developed. At the same time the development of ultrasonic nebulisers took place. During the mid 1990s hand-held and battery-operated ultrasonic nebulisers were marketed, such as the Omron NE-U03.
Simultaneously scientists and companies were developing and exploring novel technologies for liquid drug delivery. These technologies have been directed to replace and reduce current conventional jet and ultrasonic nebulisers' therapy and treatment time, which is often between five and 10 minutes. Recent focus has been on competing with pMDI and DPI therapy where the treatment consists of one or more inhalations. To date, there have been few devices marketed in the conventional jet and ultrasonic segment, only Omron and Aerogen have presented devices built on non conventional jet and ultrasonic technology (Omron's NE-U14, NE-U22 and NE-U03 and Aerogen has lately marketed their AeroNeb® and AeroNeb pro®). The only device competing with the pMDI/DPI segment that has been approved but not yet marketed is Boehringer Ingelheim's Respimat® softmist inhaler. This device is approved in the Netherlands but not marketed yet. It is probably awaiting EC mutual recognition before its European launch.
This article will give an overview of the current novel liquid inhalation technologies from a technical point of view and focus on technologies that are similar to the pMDIs and DPIs in their function. It will include a review of nine companies working with novel technologies for single inhalation liquid administration and three with potential technologies that can be used in this area.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Element Materials Unveils One of the First and Largest Air Treatment Testing Facilities Designed to Support Indoor Space Public Health Air Quality
7,500ft3 Facility Now Open to Evaluate Aerosolized Product Efficacy; Reduce Airborne Organisms, Viral Particles
More info >> |
|
 |
White Papers |
 |
|
Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control
Berlinger & Co AG
There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >> |
|
|
